---
title: "HSBC Research's Investment Ratings and Target Prices for Pharmaceutical and Biotechnology Stocks (Table)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259748360.md"
description: "HSBC Research has released its latest investment ratings and target prices for pharmaceutical and biotechnology stocks. The main stocks and their ratings include: BeiGene (Buy, target price USD 375), Innovent Biologics (Buy, target price HKD 115), Kelun-Biotech (Buy, target price HKD 549), China National Pharmaceutical Group (Buy, target price HKD 9.6), CSPC Pharma (Buy, target price HKD 10.5), Hengrui Pharma (Buy, target price RMB 79), Fosun Pharma (Hold, target price HKD 26.5), LIVZON PHARMA (Hold, target price HKD 37.23), HANSOH PHARMA (Buy, target price HKD 47)"
datetime: "2025-10-02T07:07:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259748360.md)
  - [en](https://longbridge.com/en/news/259748360.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259748360.md)
generator: "portal-rs"
---

# HSBC Research's Investment Ratings and Target Prices for Pharmaceutical and Biotechnology Stocks (Table)

HSBC Research published a research report, listing the latest investment ratings and target prices for pharmaceutical and biotechnology stocks as follows:

Stock | Investment Rating | Target Price

BeiGene (ONC.US) | Buy | USD 323 -> USD 375

Innovent Biologics (01801.HK) | Buy | HKD 110 -> HKD 115

Kintor Pharmaceutical (06990.HK) | Buy | HKD 354 -> HKD 549

China National Pharmaceutical Group (01177.HK) | Buy | HKD 8.49 -> HKD 9.6

CSPC Pharma (01093.HK) | Buy | HKD 10.7 -> HKD 10.5

Hengrui Pharma (600276.SH) | Buy | RMB 73 -> RMB 79

Fosun Pharma (02196.HK) | Hold | HKD 17.2 -> HKD 26.5

LIVZON PHARMA (01513.HK) | Hold | HKD 37.54 -> HKD 37.23

HANSOH PHARMA (03692.HK) | Buy | HKD 47

### Related Stocks

- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)
- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Did NMPA’s Acceptance of HS-20093 Just Shift Hansoh Pharmaceutical Group's (SEHK:3692) Oncology Narrative?](https://longbridge.com/en/news/298117536.md)
- [Hansoh Pharma says China NMPA accepts BLA for HS-20093 in small cell lung cancer](https://longbridge.com/en/news/298175855.md)
- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [Hansoh Pharma says China NMPA accepts HS-20093 BLA for small cell lung cancer](https://longbridge.com/en/news/297754887.md)
- [BREAKINGVIEWS-Fosun's ClubMed spinoff looks a hard sell](https://longbridge.com/en/news/297983421.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**